Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Hypoxia signaling in human diseases and therapeutic targets

Experimental & Molecular Medicine 2019³â 51±Ç 6È£ p.68 ~ 68
Lee Jae-W., Ko Jun-Suk, Ju Cynthia, Eltzschig Holger K.,
¼Ò¼Ó »ó¼¼Á¤º¸
 ( Lee Jae-W. ) 
Kyung Hee University Graduate School Department of Biomedical Science

 ( Ko Jun-Suk ) 
University of Texas Health Science Center at Houston MD Anderson UT Health Graduate School Department of Biochemistry and Molecular Biology
 ( Ju Cynthia ) 
University of Texas Health Science Center at Houston McGovern Medical School Department of Anesthesiology
 ( Eltzschig Holger K. ) 
University of Texas Health Science Center at Houston McGovern Medical School Department of Anesthesiology

Abstract


Since the discovery of hypoxia-inducible factor (HIF), numerous studies on the hypoxia signaling pathway have been performed. The role of HIF stabilization during hypoxia has been extended from the induction of a single gene erythropoietin to the upregulation of a couple of hundred downstream targets, which demonstrates the complexity and importance of the HIF signaling pathway. Accordingly, HIF and its downstream targets are emerging as novel therapeutic options to treat various organ injuries. In this review, we discuss the current understanding of HIF signaling in four different organ systems, including the heart, lung, liver, and kidney. We also discuss the divergent roles of HIF in acute and chronic disease conditions and their revealed functions. Finally, we introduce some of the efforts that are being performed to translate our current knowledge in hypoxia signaling to clinical medicine.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

SCI(E)
MEDLINE
KCI
KoreaMed
KAMS